Activating the cellular energy sensor AMPK reduced pain, lowered CGRP levels, and shifted brain immune cells from inflammatory to anti-inflammatory states in a chronic migraine mouse model.
AMPK activation shifted microglia from M1 to M2By activating AMPK, researchers switched brain immune cells from the harmful M1 (inflammatory) phenotype to the protective M2 (anti-inflammatory) phenotype, reducing CGRP expression and pain in chronic migraine mice.
What the researchers found
In a chronic migraine mouse model, repeated nitroglycerin injections progressively decreased AMPK protein expression in the trigeminal nucleus caudalis (TNC), mediated by increased UHRF1 expression. Activating AMPK with AICAR reduced pain hypersensitivity, improved activity, and decreased CGRP and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) while increasing anti-inflammatory cytokines (IL-4, IL-10). AMPK was located primarily in microglia, and AICAR shifted microglia from the inflammatory M1 phenotype (reduced iNOS) to the anti-inflammatory M2 phenotype (increased Arg1) by inhibiting the NF-κB pathway.
Why it matters
Chronic migraine involves central sensitization — where the brain's pain processing becomes amplified — but the underlying mechanisms are poorly understood. This study reveals that AMPK, a cellular energy sensor, plays a key role by controlling whether brain immune cells (microglia) promote or suppress inflammation. The involvement of CGRP, the peptide targeted by the newest migraine drugs, connects this metabolic pathway directly to the established biology of migraine treatment.
How the study worked
Chronic migraine was modeled in mice using recurrent nitroglycerin (NTG) injections. AMPK protein expression was measured in the TNC. Mice received either the AMPK activator AICAR or the inhibitor compound C via intraperitoneal injection. Researchers measured mechanical pain thresholds, activity levels, pain-like behaviors, CGRP expression, cytokine levels (IL-1β, IL-6, TNF-α, IL-4, IL-10), microglial M1/M2 polarization markers (iNOS, Arg1), and NF-κB pathway activation.
Who was studied
Mice with recurrent nitroglycerin-induced chronic migraine
What this study cannot tell us
This is a preclinical mouse study using a chemical (nitroglycerin) model of chronic migraine, which may not fully recapitulate human migraine pathophysiology. AICAR was delivered by intraperitoneal injection, and its brain penetrance and specificity for AMPK may limit translational relevance. Specific quantitative results (fold changes, p-values for behavioral measures) are not reported in the abstract. The connection to human CGRP-targeted therapies is mechanistic inference, not direct clinical evidence.
How to read the evidence
This is a preclinical mechanistic study in a mouse model of chronic migraine. While it provides compelling evidence for a new therapeutic pathway, the chemical migraine model and the use of a non-specific AMPK activator limit direct clinical translation. No human data is available for this approach.
When this study was published
Published in 2024, this is a recent contribution to the growing understanding of metabolic dysfunction in chronic migraine and its intersection with CGRP-mediated neuroinflammation.
The bigger picture
This study bridges two emerging areas of migraine research: the role of metabolic dysfunction (energy sensing via AMPK) and neuroinflammation (microglial activation and CGRP release). The finding that AMPK controls microglial polarization and CGRP expression suggests that metabolic interventions — perhaps including existing AMPK activators like metformin — could complement current CGRP-targeted migraine therapies. It also provides a mechanistic link between the energy disorders and neurogenic inflammation observed in chronic migraine patients.
Questions still open
- Could existing AMPK activators like metformin be repurposed as adjunctive therapy for chronic migraine?
- Does AMPK dysfunction also contribute to episodic migraine, or is it specific to the chronic form?
- How does the AMPK-mediated reduction in CGRP compare in magnitude to the CGRP blockade achieved by anti-CGRP monoclonal antibodies?
Common questions
What is AMPK and what does it have to do with migraines?
How does this relate to current migraine drugs like Aimovig (erenumab)?
Read the original research
AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization.
The journal of headache and pain, 25(1), 29
Citation
Lu, Guangshuang; Xiao, Shaobo; Meng, Fanchao; Zhang, Leyi; Chang, Yan; Zhao, Jinjing; Gao, Nan; Su, Wenjie; Guo, Xinghao; Liu, Yingyuan; Li, Chenhao; Tang, Wenjing; Zou, Liping; Yu, Shengyuan; Liu, Ruozhuo. (2024). AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization.. The journal of headache and pain, 25(1), 29. https://doi.org/10.1186/s10194-024-01739-w